Cannabinoids and PPAR Ligands: The Future in Treatment of Polycystic Ovary Syndrome Women with Obesity and Reduced Fertility

Cannabinoids (CBs) are used to treat chronic pain, chemotherapy-induced nausea and vomiting, and multiple sclerosis spasticity. Recently, the medicinal use of CBs has attracted increasing interest as a new therapeutic in many diseases. Data indicate a correlation between CBs and PPARs via diverse me...

Full description

Saved in:
Bibliographic Details
Published in:Cells (Basel, Switzerland) Switzerland), 2022-08, Vol.11 (16), p.2569
Main Authors: Przybycień, Piotr, Gąsior-Perczak, Danuta, Placha, Wojciech
Format: Article
Language:English
Subjects:
Cannabinoids
Care and treatment
CB1R
CB2R
Cell receptors
Chemotherapy
Chronic pain
Endocannabinoid system
endocannabinoids
Glucose metabolism
Health aspects
Infertility
Insulin resistance
Ligands (Biochemistry)
Lipid metabolism
Metabolic pathways
Multiple sclerosis
Nausea
Obesity
Pathophysiology
PCOS
Peroxisome proliferator-activated receptors
Polycystic ovary syndrome
PPARs
Review
Spasticity
Stein-Leventhal syndrome
Therapeutic applications
Therapeutic targets
Vomiting
Womens health
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Cannabinoids (CBs) are used to treat chronic pain, chemotherapy-induced nausea and vomiting, and multiple sclerosis spasticity. Recently, the medicinal use of CBs has attracted increasing interest as a new therapeutic in many diseases. Data indicate a correlation between CBs and PPARs via diverse mechanisms. Both the endocannabinoid system (ECS) and peroxisome proliferator-activated receptors (PPARs) may play a significant role in PCOS and PCOS related disorders, especially in disturbances of glucose-lipid metabolism as well as in obesity and fertility. Taking into consideration the ubiquity of PCOS in the human population, it seems indispensable to search for new potential therapeutic targets for this condition. The aim of this review is to examine the relationship between metabolic disturbances and obesity in PCOS pathology. We discuss current and future therapeutic interventions for PCOS and related disorders, with emphasis on the metabolic pathways related to PCOS pathophysiology. The link between the ECS and PPARs is a promising new target for PCOS, and we examine this relationship in depth.
ISSN:2073-4409
2073-4409
DOI:10.3390/cells11162569